Viscoelastic testing Point-of-Care D68.9 A41.9
Conditions
Interventions
Group 1: Healthy Subjects: Blood samples are manually transported for viscoelastometry diagnostics.
Group 2: Healthy Subjects: Blood samples are transported via pneumatic tube system for viscoelastome
Sponsors
Universitätsklinikum Dresden
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Healthy Subjects: Age = 18 years No acute illnesses No known pregnancy No chronic diseases involving the coagulation system No medication intake within the last seven days Signed informed consent Inclusion Criteria for Patients: Age = 18 years Critical illness requiring intensive care (SOFA score = 9) Diagnosis of sepsis or septic shock within the last 48 hours (according to SEPSIS-3 definition) Ongoing anticoagulant therapy (UFH, NMH, or Argatroban) at any dosage Signed informed consent from the patient or a legal representative (if the patient is unable to provide consent)
Exclusion criteria
Exclusion criteria: Failure to meet the inclusion criteria Known hereditary coagulation disorder Known acquired coagulation disorder (for healthy subjects)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the VETaPT study is to investigate whether transport via a pneumatic tube system (PTS) has a clinically relevant impact on the results of coagulation tests in healthy subjects and critically ill intensive care patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective of the VETaPT study is to determine whether a threshold exists for the forces induced by the pneumatic tube system, beyond which the impact on coagulation test results becomes clinically relevant. | — |
Countries
Germany
Contacts
Public ContactMartin Mirus
Universitätsklinikum Dresden Klinik für Anästhesiologie und Intensivtherapie
Outcome results
None listed